PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.56%
R&D reduction while AVXL shows 12.43% growth. Joel Greenblatt would examine competitive risk.
-79.23%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-99.88%
Other expenses reduction while AVXL shows 0.22% growth. Joel Greenblatt would examine efficiency.
-74.55%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-74.55%
Both companies reducing total costs. Martin Whitman would check industry trends.
-99.95%
Both companies reducing interest expense. Martin Whitman would check industry trends.
609.47%
D&A growth above 1.5x AVXL's 0.22%. Michael Burry would check for excessive investment.
90.56%
EBITDA growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
74.50%
Operating income growth exceeding 1.5x AVXL's 35.83%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
136.63%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
91.74%
Pre-tax income growth while AVXL declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-502.21%
Tax expense reduction while AVXL shows 100.47% growth. Joel Greenblatt would examine advantage.
91.74%
Net income growth exceeding 1.5x AVXL's 33.05%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
91.71%
EPS growth exceeding 1.5x AVXL's 33.04%. David Dodd would verify competitive advantages.
91.71%
Diluted EPS growth exceeding 1.5x AVXL's 33.04%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.